(Q42854744)

8 November 2017

Translation of anticancer efficacy from nonclinical models to the clinic (English)

1 reference

8 November 2017

M Stroh

1

1 reference

8 November 2017

D G Duda

2

1 reference

8 November 2017

C H Takimoto

3

1 reference

8 November 2017

S Yamazaki

4

1 reference

8 November 2017

P Vicini

5

1 reference

8 November 2017

language of work or name

1 reference

6 August 2014

1 reference

CPT: pharmacometrics & systems pharmacology

8 November 2017

1 reference

8 November 2017

3

1 reference

8 November 2017

e128

1 reference

Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers

8 November 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4150926

Targeting placental growth factor/neuropilin 1 pathway inhibits growth and spread of medulloblastoma

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4150926

Translational pharmacokinetic-pharmacodynamic modeling from nonclinical to clinical development: a case study of anticancer drug, crizotinib

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4150926

CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies?

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4150926

Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors.

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4150926

Preclinical pharmacokinetic/pharmacodynamic models of gefitinib and the design of equivalent dosing regimens in EGFR wild-type and mutant tumor models

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4150926

Trends in the use and role of biomarkers in phase I oncology trials

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4150926

Auditing the pharmacological accounts for Hsp90 molecular chaperone inhibitors: unfolding the relationship between pharmacokinetics and pharmacodynamics.

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4150926

Why is cancer drug discovery so difficult?

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4150926

Novel Phase I dose de-escalation design trial to determine the biological modulatory dose of the antiangiogenic agent SU5416.

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4150926

Telomerase as a Target for Cancer Immunotherapy

16 August 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FPSP.2014.28

21 January 2018

Identifiers

DOI

10.1038/PSP.2014.28

1 reference

8 November 2017

1 reference

8 November 2017

PubMed publication ID

25098530

1 reference